Clinical Trial Update: Phase 2/3 Study of IGSC, 20% in PIDD [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update for IGSC 20% in primary immunodeficiency diseases (PID) with completed status and results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• IGSC

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-02-15